Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of ozanimod on myelin dynamics and neurodegeneration in relapsing-remitting multiple sclerosis
2024-513960-24-00Phase 4Authorised
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ozanimod in multiple sclerosis (MS) (2 arms), sponsored by IRCCS Ospedale San Raffaele. Primary endpoints: Global brain atrophy (percent brain volume change), Regional gray matter volume and 3 more. Planned start Jul 2024; status: authorised.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-513960-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513960-24-00.